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ABSTRACT 
RHO family proteins and other intracellular proteins are prenylated with a 20-
carbon lipid—a product of the cholesterol synthesis pathway—by protein 
geranylgeranyltransferase type I (GGTase-I). Prenylation is widely believed to 
target proteins to membranes where they encounter effector molecules that 
stimulate GTP-binding and activation. However, my host group found that 
knockout of GGTase-I in mouse macrophages (Pggt1bΔ/Δ) actually increases GTP-
loading of RHO proteins such as RAC1, RHOA, and CDC42, and also increases 
proinflammatory signaling and cytokine production, and induces severe rheumatoid 
arthritis. These results suggest that prenylation may inhibit rather than stimulate 
RHO protein function. The mechanisms underlying increased GTP-loading and 
exaggerated innate immune responses in the absence of GGTase-I are not known. 
During my PhD, I have addressed these issues in two independent but 
interconnected projects. 
In project 1, we found that there is an imbalance between inflammatory and anti-
inflammatory cytokines produced by Pggt1bΔ/Δ macrophages. We also found that 
knockout of GGTase-I prevents the interaction between KRAS and PI3K catalytic 
subunit p110δ and that this reduces signalling through the PI3K-AKT-GSK3β 
pathway. Moreover, Pggt1bΔ/Δ macrophages exhibit increased caspase-1 activity 
that is directly responsible for the production of active interleukin IL-1β, and that 
this effect requires the MEFV (pyrin) inflammasome. Thus, we conclude that 
GGTase-I promotes an association between KRAS and p110δ and thereby controls 
major inflammatory pathways in macrophages. 
In project 2, we tested the importance of RHO proteins in the development of 
arthritis in Pggt1bΔ/Δ mice. We found that knockout of Rac1 (i.e., in 
Pggt1bΔ/ΔRac1Δ/+ mice), but not Rhoa and Cdc42, markedly reduced inflammatory 
cytokine production and arthritis in Pggt1bΔ/Δ mice. We also found that non-
prenylated RAC1 bound more strongly to the RAS GTPase-activating-like protein 
1 (IQGAP1) – which facilitated RAC1 GTP-loading and activation. Knockout of 
Iqgap1 in Pggt1bΔ/Δ mice abolished cellular phenotypes in vitro and inhibited 
arthritis in vivo. Thus, we conclude that blocking prenylation stimulates RAC1 
effector interactions and activates wide-spread pro-inflammatory signaling. Thus, 
prenylation normally restrains innate immune responses by inhibiting RAC1 
effector interactions. 
Keywords: CAAX proteins, GGTase-I, RAC1. ISBN: 978-91-7833-233-5 
  
  
  
SAMMANFATTNING 
 
Enzymet geranylgeranyltransferas typ I (GGTase-I) kopplar på en fettmolekyl på ett 100-tal 
proteiner inne i celler i en process som kallas prenylering. En klass proteiner som prenyleras heter 
RHO-proteiner. RHO-proteiner är viktiga för funktionen hos inflammatoriska celler som aktiveras 
vid infektioner och skador. Man har länge tänkt att prenylering gör att RHO-proteinerna lättare kan 
binda till membran i cellen där de kommer i kontakt med proteiner som aktiverar RHO-proteinerna. 
När vi först studerade detta fann vi att om man knockar ut genen som kodar för GGTase-I i 
makrofager hos möss så hindras modifieringen av RHO-proteiner, som förväntat, men istället för att 
inaktiveras så ansamlade sig RHO-proteinerna i sin aktiva form; och makrofagerna blev hyperaktiva 
och orsakade inflammation och ledgångsreumatism. Vi är också intresserade av hur de 
kolesterolsänkande statinerna kan aktivera RHO-proteiner och stimulera produktion av 
inflammatoriska substanser. När statinerna hämmar kolesterolsyntesen så hämmas också 
produktionen av den fettmolekyl som kopplas på RHO-proteinerna. I denna avhandling har jag 
försökt svara på dessa frågor. 
I det första projektet, fann vi att i makrofager som saknar GGTase-I aktiverar pyrin-inflammasomen 
och caspas-1 som leder till produktion av en inflammationsdrivande substans som heter interleukin 
1-beta (IL-1β). I det andra projektet fann vi att RHO-proteinet RAC1 ensamt ansvarar för 
utvecklingen av inflammation och reumatism i mössen. Vi fann vidare att när RAC1 inte prenyleras, 
så blir det hyperaktivt på grund av att det får en kraftigt ökad förmåga att binda till proteinerna 
TIAM1 och IQGAP1 vilka stimulerar signalering till proteinerna NF-kB och som tidigare, till 
inflammasomen och caspas-1. För att bevisa inblandningen av RAC1 och IQGAP1 så knockade vi 
först ut genen för RAC1 och fann att inflammationen och reumatismen så gott som försvann; och 
när vi knockade ut genen för IQGAP1 fann vi att RAC1 (och övriga RHO-proteiner) återfick normal-
aktivitet och att inflammationen och reumatismen botades. Vi fann också att statiner hämmar 
prenylering av RAC1 och ökar produktionen av IL-1β och att denna effekt beror av IQGAP1. Från 
dessa studier kan vi dra slutsatsen att när prenylering hämmas, så binder RAC1 till IQGAP1 och 
TIAM1, blir hyperaktivt och orsakar sen massiv inflammation. Detta betyder i sin tur att prenylering 
normalt sett fungerar som en broms för immunförsvaret genom att hämma RAC1-aktivering. I ett 
bredare perspektiv leder våra resultat till en ökad förståelse för prenylering i sig, men vi identifierar 
också IQGAP1, och till viss mån även RAC1, som nya potentiella måltavlor för läkemedel som kan 
användas för behandling av en ovanlig men allvarlig autoinflammatorisk sjukdom som heter 
mevalonate kinase deficiency (MKD). 
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AT1 Angiotensin type 1 
CDC42 Cell division control protein 42 homolog 
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GEF Guanine nucleotide exchange factor 
GGPP Geranylgeranyl pyrophosphate 
GGTase-I Geranylgeranyltransferase type I 
GGTI Geranylgeranyltransferase type I inhibitor 
GTP Guanosine triphosphate 
GTPase Guanosine tri-phosphatase 
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IQGAP2 Ras GTPase-activating-like protein IQGAP2 
JNK c-Jun N-terminal kinases 
LDL Low-density lipoprotein 
MAPK mitogen-activated protein kinase 
MCP-1   Monocyte chemoattractant protein 1 
MEFV Pyrin 
MKD Mevalonate kinase deficiency 
MS Multiple sclerosis 
MMP13 Matrix metallopeptidase 13 
NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells 
NLRP1 NACHT, LRR and PYD domains-containing protein 1 
NLRC4 NLR family CARD domain-containing protein 4 
PAK1 P21 activating kinase 
PAMP Pathogen associated molecular patterns 
PDEδ Phosphodiesterase-δ 
PI3K Phosphoinositol-3-kinase 
vii 
 
PRR Pathogen recognised receptors 
RA Rheumatoid arthritis 
RAC1 Ras-related C3 botulinum toxin substrate 1 
RAC2 Ras-related C3 botulinum toxin substrate 2 
RAC3 Ras-related C3 botulinum toxin substrate 3 
RCE1 Ras-converting enzyme 1 
RHOA Ras homolog gene family, member A 
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ROS Reactive oxygen species 
ROCK1/2 RHO associated coiled-coil-containing protein kinase 1 and 2 
SLE Systemic lupus erythematous therapy 
SmgGDS small G-protein dissociation stimulator  
TIAM1 T-cell lymphoma invasion and metastasis-inducing protein 1  
ZMPSTE24 zinc metalloproteinase Ste24 homologue  
 
 1 
 
2 INTRODUCTION 
CAAX-PROTEINS 
CAAX proteins are a group of proteins that contain 
a CAAX sequence at the carboxyl-terminal end 
where C is a cysteine; A are aliphatic amino acids; 
and X can vary. CAAX proteins undergo a three-
step post-translational modification process: First, 
the CAAX-motif of a protein is recognized by 
either of two enzymes called 
geranylgeranyltransferase-I (GGTase-I) or 
farnesyltransferase (FTase) which are responsible 
for transferring a C20 geranylgeranyl lipid or a C15 
farnesyl lipid (prenyl group) to the cysteine 
residue of the CAAX-motif, respectively. This 
process is collectively called protein prenylation. 
Second, the endoprotease RAS-converting 
enzyme (RCE1) cleaves off the terminal –AAX 
sequence. And third, the newly-exposed 
isoprenylcysteine residue is methyl-esterified by 
isoprenylcysteine carboxyl methyltransferase 
(ICMT) (Fig. 1). Prenylation is believed to be 
essential for proper function of CAAX proteins 
because it stimulates membrane targeting, 
interaction with effector proteins, and activation 
(1). Moreover, these modifications help to decide 
the localisation of proteins to specific parts of the 
cell, improving protein-protein interactions and 
modulating protein stability. 
In the last three decades, prenylation has generated a broad interest in the research 
community due to the involvement of CAAX proteins in the pathophysiology of 
various diseases. Progeria is a well-known example of one such disease, where the 
toxic accumulation of prenylated prelamin-A drives the disease (2, 3), and where 
inhibitors of FTase and recently also ICMT are tested as therapeutic options. Cancer 
is another example; it has been found that prenylated RAS proteins are involved in 
the pathogenesis of at least 30% human cancers. Lots of research has focused on 
inhibiting CAAX protein processing enzymes as a strategy to block the activity of 
oncogenic RAS (4).  
Fig. 1. Posttranslational modification 
of CAAX proteins. The cysteine residue 
of the CAAX box is prenylated by 
GGTase-I or FTase; the –AAX tripeptide 
is cleaved off by RCE1, and the newly-
formed prenylcysteine residue is 
methylated by ICMT. (Picutre: Emil 
Ivarsson) 
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The history of protein prenylation 
In the genome, there are several hundred proteins that terminate with a CAAX 
sequence. At least 100 of those are predicted to be farnesylated or 
geranylgeranylated (5-8). The first evidence of protein prenylation was discovered 
in the late 1970s, when the fungal mating factor rhodotorucine A was found to 
contain a farnesyl lipid attached to a cysteine residue close to the carboxyl terminus 
(9). More evidence of protein prenylation emerged in studies on statins, a group of 
drugs that inhibit HMG-CoA (3-hydroxy-3-methyl-glutaryl-Coenzyme A) 
reductase—the enzyme which catalyzes the committed step in cholesterol 
biosynthesis (10). A key finding came in a study where statin-induced proliferation 
arrest was not rescued by addition of sterols, which suggested that some 
intermediary by-products in the cholesterol pathway are involved in controlling cell 
proliferation (11, 12). In support of that, further evidence emerged in 3H-
mevalonate-labelling experiments in cells lacking HMG-COA reductase, in which 
researchers found incorporation of 3H-mevalonate in cellular proteins, suggesting 
that these proteins were prenylated (13). Later, a nuclear protein Lamin B (a nuclear 
lamina protein) was discovered as the first prenylated protein in mammals, but it 
was not known at the time which prenyl moiety was attached (14). Finally, the 
interest in protein prenylation began to attract worldwide attention when it was 
discovered that RAS proteins are farnesylated, and that farnesylation was essential 
for the ability of mutant RAS to localize to the plasma membrane, interact with 
RAF and transform cells (15-17). Due to this finding, an intense race to develop 
farnesyltransferase inhibitors started.  
Prenylation by GGTase-I and FTase-I 
As outlined earlier, the isoprenoids used by GGTase-I and FTase are the cholesterol 
biosynthetic intermediates farnesyl pyrophosphate (FPP, 15 carbons) and 
geranylgeranyl pyrophosphate (GGPP, 20 carbons) produced from isopentenyl 
diphosphate. FTase and GGTase-I enzymatic activity involves attaching an FPP or 
a GGPP molecule, respectively, to the cysteine residue of the CAAX motif. The 
attachment is made with a thioether linkage (18). Both FTase and GGTase-I are 
comprised of heterodimers, and they reside in the cytosol. They share a common 
alpha subunit (encoded by the gene FNTA) but have distinct catalytic beta subunits 
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(encoded by FNTB and PGGT1B), which are vital to performing their functions 
(19-21). 
The question of what factors determine whether a CAAX protein will undergo 
farnesylation or geranylgeranylation, received much attention in the early nineties. 
The research led up to the understanding that it is the `X` residue in the CAAX motif 
that dictates if the protein is farnesylated or geranylgeranylated (22-25). More 
specifically, CAAX proteins become farnesylated if the X residue is Methionine (M), 
Serine (S), Glutamine (Q), or Alanine (A); whereas proteins become 
geranylgeranylated by GGTase-I if `X` is either Leucine (L) or phenylalanine (F) 
(25). HRAS, KRAS, NRAS, prelamin A, and lamin B are the most studied 
substrates for FTase, whereas small GTP-binding proteins like RAS homolog gene 
family, member A (RHOA), Ras-related C3 botulinum toxin substrate 1 (RAC1), 
and Cell division control protein 42 homolog (CDC42) are the most studied 
substrates for GGTase-I (5, 23, 26). Although both enzymes are highly specific 
towards their target proteins, in some cases they compensate each other via cross-
prenylation or alternative prenylation. Examples of this are KRAS and NRAS, two 
well-known isoforms of RAS are normally farnesylated, but studies found that 
those two isoforms are geranylgeranylated by GGTase-I in cells where FTase is 
inhibited (27). This cross prenylation phenomenon has been proposed as an 
explanation of how RAS-driven cancers manage to deal with farnesyltransferase 
inhibitor (FTI) treatment (28). This idea was also proven with genetic experiments 
in mouse models (29, 30).  
The regulation of prenylation is not fully understood, but recent studies have 
identified interesting mechanisms that regulate prenylation through splice variants 
of SmgGDS (small G-protein dissociation stimulator), which is a nucleotide 
exchange factors specific for CAAX proteins that contain carboxyl-terminal 
polybasic region. They have been found to regulate the entrance and passage of 
CAAX proteins through the prenylation pathway (31).  SmgGDS-558 and SmgGDS-
607 are two splice variants that are involved in the regulation of prenylation by 
recognizing the CAAX sequence. SmgGDS-558 forms a complex with 
geranylgeranylated CAAX proteins that are processed by GGTase-I, while 
SmgGDS-607 associates with unprenylated CAAX proteins that eventually become 
geranylgeranylated by GGTase-I. These two then regulate trafficking of the CAAX 
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proteins to the plasma membrane (31, 32). This novel mechanism depicts one facet 
of how prenylation regulates the handling and trafficking of CAAX proteins to the 
plasma membrane.  
Post-Prenylation processing by RCE1 and ICMT 
After prenylation, the CAAX proteins are further modified by RAS converting 
enzyme (RCE1), an endoprotease that clips off the -AAX tripeptide sequence from 
CAAX box. RCE1 was first found in a yeast screen designed to identify genes 
involved in RAS protein processing. Subsequently, mammalian RCE1 was 
identified based on homology to the yeast RCE1 and is believed to proteolyze most 
isoprenylated CAAX proteins (33, 34). Further studies led to the discovery of 
another yeast protease, sterile24 (Ste24), which is responsible for proteolysis of the 
–AAX sequence from yeast a-factor (Ste24 also cleaves a-factor upstream of the 
fully processed farnesylmethylcysteine). Ste24 was identified in the late 90ies at 
UC Berkeley (35-37). The mammalian orthologue was subsequently given the 
cumbersome name zinc metalloproteinase Ste24 homologue (ZMPSTE24). The 
only mammalian substrate for ZMPSTE24 identified thus far is prelamin A which 
is an intermediate filament protein of the nuclear lamin (37, 38). 
The final enzymatic processing step in the posttranslational maturation of CAAX 
proteins is carboxyl methylation of the isoprenylcysteine residue. The enzyme 
responsible for this step was also identified in yeast and named Ste24 (39). Its 
mammalian orthologue, isoprenylcysteine carboxyl methyltransferase (ICMT) was 
identified later (40, 41). This final processing step, together with prenylation, 
renders the carboxyl-terminal end of the protein hydrophobic and prone to associate 
with membranes (42, 43). Both RCE1 and ICMT resides in the endoplasmic 
reticulum that is responsible for the trafficking of farnesylated and 
geranylgeranylated proteins to the plasma membrane. Furthermore, RCE1 and 
ICMT have been explored as potential drug targets as they both process all the main 
RAS isoforms, and both the farnesylated and geranylgeranylated forms (44).   
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Importance of protein prenylation  
Membrane targeting 
The trafficking of CAAX proteins to their target location on membranes is controlled 
and tightly regulated by specific cytosolic proteins and chaperones. RHO protein 
GDP dissociation inhibitors (RHOGDIs) and 14-3-3 proteins, for instance, bind to 
geranylgeranylated forms of RHO family proteins and RND subfamily of RHO 
proteins, respectively (45, 46). Recent structural studies of these proteins have 
revealed the presence of hydrophobic pockets that can accommodate the prenyl 
moieties of CAAX proteins. For example, RHO-GDI1 has a pocket in which the 
geranylgeranyl group of RHOA fits perfectly (47). But interestingly, in GGTase-I-
knockout cells, where RHOA is not prenylated, RHOA binds just as strongly as in 
wild-type cells (48). These pockets strengthen the association between them and 
help to restrict the release of CAAX proteins to further signaling (45, 49). Similar to 
the above, phosphodiesterase-δ (PDEδ) forms a complex with farnesylated RAS 
and restricts the release of RAS to oncogenic signaling (50, 51).  
Cellular roles of prenylation 
Farnesylation is required for RAS activation, and this phenomenon has caught the 
attention of the scientific community because 30% of human cancers have an 
activating mutation is a RAS gene. Thus, inhibiting farnesylation seemed in the 
early nineties to be the key to combat RAS-induced cancers, many of which have a 
high mortality rate (i.e., pancreatic, lung, and colon cancer). A race between 
academic laboratories and pharmaceutical companies ensued and several FTIs were 
developed. The FTIs inhibited HRAS-driven cancers quite effectively in mouse 
models and several FTIs produced anti-proliferative effects in different types of 
cancer cells via cell cycle arrest in the G1 or G2/M phase of the cell cycle (52). 
These preclinical studies raised the hope in the field that FTIs might indeed be used 
to stop RAS induced cancers in its tracks. 
Contrary to expectations, clinical trials with FTIs showed no beneficial effect in the 
treatment of cancer. It was quickly discovered that when FTase is inhibited KRAS 
and NRAS can become geranylgeranylated by GGTase-I and continue to function 
normally. This was troubling as most RAS-mutant cancers involve mutations in 
KRAS and NRAS. HRAS mutations, which the preclinical studies relied on, is 
exclusively farnesylated. Moreover, the observed antiproliferative effects with FTIs 
could not be solely attributed to the inhibit activation of RAS, which indicates the 
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possible involvement of other CAAX proteins in the control of cell proliferation (26, 
52). This argument was supported by genetic studies in our own laboratory: 
Knockout of Fntb caused cell proliferation arrest in both KRAS and HRAS mutant 
cells and improved survival in mice with KRAS-induced lung cancer—despite the 
fact that KRAS was geranylgeranylated and fully functional (29).  
Further research revealed that centromere-associated protein E and F (CENP-E and 
CENP-F), whose activation are dependent on farnesylation, are involved in the 
control of cell cycle progression at metaphase (53, 54). Later, it was discovered that 
the nuclear proteins Lamin B1 and Lamin B2 are farnesylated proteins that are also 
involved in regulation of cell proliferation and senescence (55, 56).  In addition to 
that, the lamin A (LMNA) precursor, prelamin A is involved in the progression of 
Hutchinson-Gilford progeria syndrome (HGPS), a rare ageing disorder caused by 
mutations in LMNA (2). Researchers have also identified two other important 
farnesylated proteins, RHEB GTPases and liver kinase B (LKB), that play a central 
role in cellular energy metabolism through mammalian target of rapamycin 
(mTOR) and AMP activated protein kinase (AMPK) signaling (57, 58). Taken 
together, it is hypothesized that inhibition of FTase may block other prenylated 
proteins (CENP-E, CENP-F, lamin A/C, lamin B, RHEB GTPases, and LKB) along 
with RAS to exert anti-proliferative effects. 
The disappointing lack of progress with FTIs in clinical trials, cross prenylation of 
RAS, and the involvement of geranylgeranylated proteins (RALA, RALB, RHOC, 
RAC1 and CDC42) cancer progression, shifted the focus to GGTase-I as a potential 
target to combat cancer (28, 59-65). Unlike FTase, GGTase-I is essential for 
modification of many CAAX proteins, and thus blocking GGTase-I activity could 
potentially inhibit the function of many CAAX proteins at once. Similar to FTIs, 
GGTase-I inhibitors (GGTIs) cause cell cycle arrest, but here primarily at G0 and 
G1 phase and those effects might be mediated by downstream signaling of RHO 
proteins (66). Our lab has shown supporting evidence of this in a study where 
genetic inactivation of GGTase-I reduces KRAS-induced lung cancer and 
myeloproliferative disease (MPD) (29, 30).   
Importantly, many CAAX proteins, including the RHO family proteins, are involved 
in multiple functions of inflammatory cells. During my PhD, I have focused on the 
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importance of GGTase-I-mediated geranylgeranylation of RHO family proteins and 
the impact of inhibiting this enzyme for the progression of inflammatory diseases. 
RHO proteins 
RHO family proteins are a subcategory of CAAX proteins that are low-molecular-
weight (~21 kDa) GTP-binding proteins that act like molecular switches and cycle 
between inactive GDP (guanosine diphosphate) bound and active GTP (guanosine 
triphosphate) bound forms (Fig. 2) (2). Conversion of GDP to GTP (activation) is 
catalyzed by guanine nucleotide exchange factors (GEFs); GTP hydrolysis to GDP 
(inactivation) is stimulated by GTPase-activating proteins (GAPs). RHO protein 
GDP dissociation inhibitors (RHO-GDIs) are key regulatory enzymes that form 
complexes with the inactive GDP-bound form of RHO proteins and keep them 
sequestered in the cytosol (67). Different external signals and growth factors induce 
dissociation of RHO proteins from the RHO-GDI complex, which leads to the 
availability of RHO proteins for membrane targeting, GTP-binding, activation and 
further signaling. 
Furthermore, other types of proteins stabilizes RHO proteins in their active GTP-
bound form, e.g. RAS GTPase-activating like proteins IQGAP1 (IQGAP1) and 
RAS GTPase-activating like proteins IQGAP2 (IQGAP2) (68, 69). Balancing 
between active and inactive forms of RHO proteins is very important in order to 
regulate specific cellular functions such as actin cytoskeleton remodeling, cell cycle 
progression, proliferation, migration, production of growth factors, and cytokine 
release (70-72). Inappropriate signaling of RHO family GTPases contributes to the 
pathogenesis of cancer (73-75), inflammation (76), and cardiovascular diseases 
(77).  
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Fig. 2. Activation and inactivation of the RHO family protein RAC1. Prenylation is important 
for the interaction between RAC1 and RHO-GDI. RHO family proteins (including RAC1) form 
complexes with RHO-GDI in the cytosol in their inactive GDP-bound forms. RAC1-GEFs and 
RAC1-GAPs stimulate GTP binding and GTP hydrolysis, respectively, and thereby activate and 
inactivate RAC1. Growth factors and extracellular signals result in the release of RAC1-GDP from 
the RAC1-GDP-RHOGDI complex. RAC1 then transfers to the plasma membrane and is 
subsequently converted into its active GTP-bound form through the action of a GEF. Once RAC1 is 
activated, it interacts with different kinds of effectors (e.g., IQGAP1, IQGAP2) to signal 
downstream to control cell proliferation, migration, and morphology. Eventually, GAPs assist in the 
hydrolysis of the GTP and RAC1 is inactivated. (Picture: Emil Ivarsson)  
To date, 22 mammalian members of RHO family proteins have been identified, and 
they further subdivided into RAC subfamily GTPases, CDC42 subfamily GTPases, 
RHOA subfamily GTPases and other RHO GTPases (78). Among them, RAS-
related C3 botulinum toxin substrate 1 (RAC1), RAS homolog gene family, 
member A (RHOA), and Cell division control protein 42 homolog (CDC42) are the 
most well-studied members of this group (78). The section below describes key 
molecular biology events involved in activation of RHO family proteins and their 
roles in the progression of inflammatory diseases.  
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RAC1 
The RAC subfamily of GTP binding proteins consists of RAC1, RAC2, RAC3 and 
RHOG. RAC1 is the most well-studied among them due to its critical involvement 
in the regulation of a wide range of cellular functions, such as cytoskeletal 
modifications—especially lamellipodia formation—migration and invasion; 
generation of reactive oxygen species (ROS) through NADPH oxidase; and 
initiation of the inflammatory response (79-81). RAC1 is expressed ubiquitously in 
most cells in the body, while RAC2 and RAC3 expression are limited to 
hematopoietic cells and neural cells, respectively (82-84). 
Similar to other RHO family proteins, RAC1 acts as a tightly controlled molecular 
switch between inactive GDP bound state, and active GTP bound state. TIAM1 (T-
cell lymphoma invasion and metastasis-inducing protein-1), VAV1 (Proto-
oncogene VAV), VAV2 (Proto-oncogene vav) and β-pix (RHO guanine nucleotide 
exchange factor 7) are the most commonly known GEFs, which catalyze the release 
of GDP and recruitment of GTP in RAC1 leading to RAC1 activation (85). RAC-
GAP1, cdGAP, and RICS are GAPs involved in GTP hydrolysis (86-88). In 
addition, some proteins induce stability to the GTP form of RAC1, including 
IQGAP1 (89, 90).  
Several transmembrane receptors with the help of their ligands can stimulate the 
conversion of active RAC1 and then transmit signals to effectors that trigger a wide 
range of physiological outcomes. P21 activating kinase (PAK1) is the canonical 
effector downstream of RAC1 that transmits RAC1 downstream signals. Activated 
RAC1 binds to PAK and then stimulates PAK kinase activity, which in turn 
regulates cytoskeleton remodeling, adhesions, gene transcription via control of 
different signaling cascades like c-JUN N-terminal kinase (JNK), nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-B), and canonical JNK 
regulated WNT signaling (91-96). RAC1 plays an essential role in activation of 
NADPH oxidase complex in immune cells including macrophages. Incorporation 
of activated RAC1 into NADPH complex is an essential requirement to generate 
ROS, and then it stimulates superoxide production to provide an immune response 
against invading pathogens (97, 98). Furthermore, RAC1 is required for 
immunoglobulin receptor–mediated phagocytosis to promote inflammatory 
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response via activation of MAPK (mitogen-activated protein kinase) and JNK (99). 
Overexpression of the active form of RAC1 has also been identified in many tumor 
types, and RAC1 is sometimes required for oncogene-induced transformation, 
including by RAS and TIAM1 (100-105).  
Aberrant signaling of RAC-family GTPases, especially RAC1, is found in the 
progression of several inflammatory diseases including osteoarthritis (106, 107), 
Crohn´s disease (108), psoriasis (109) and mevalonate kinase deficiency (110). 
Active RAC1 plays an important role in eliciting an immune response against 
infection. ROS production (79, 111), and NF-B activation (111, 112), are two key 
signaling pathways involved in RAC1-mediated inflammatory disease progression. 
Activated RAC1 uses those signaling pathways to trigger production of several 
inflammatory mediators, including interleukins (e.g., IL-6 and TNF-α) (113) and 
matrix metalloproteinase (MMP13) (106, 114) that drive disease progression. A 
few studies suggested that blocking RAC1 might be a strategy to treat inflammatory 
disorders such as arthritis and autoimmune disorders (115, 116). 
RHOA 
RHOA is a ubiquitously expressed RHO family GTPase protein involved in 
regulation of different cellular events including cytoskeleton modification, 
formation of stress fibers, focal adhesions, and cell to cell adhesions, cell to matrix 
adhesions and cell migration (117-119). RHOA-triggered cellular responses are 
mediated by a RHOA effector called RHO associated coiled-coil-containing protein 
kinase (ROCK). The ROCK inhibitor Y27632 is often used to block RHO mediated 
cellular responses. These include the inhibition of RAS-induced oncogene 
transformation (120), NFB-dependent cytokine production in experimental colitis 
(121), MCP-1-induced chemotaxis (122), vasoconstriction (123), and cardiac 
hypertrophy (124, 125). Fasudil is the only ROCK inhibitor approved for clinical 
use, and is used to treat cerebral vasospasm due to its potent vasodilation effects 
(126). 
Mounting evidence shows that increased RHOA signaling is a hallmark in 
pathogenesis of inflammatory diseases, including inflammatory Crohn’s disease 
(121), ulcerative colitis (127), cardiac hypertrophy (128) and asthma (129). Statins, 
the drugs that lower cholesterol by blocking HMG-CoA reductase activity, display 
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beneficial cardiovascular effects that have been linked to reduced prenylation of 
RHOA. Blocking RHOA protects mice from cardiac hypertrophy-induced ischemia 
(130). Subsequently, a strategy was proposed to block RHO proteins signaling by 
statins or GGTIs to prevent progression of inflammatory diseases such as 
atherosclerosis. However, research in our lab showed that this was not accurate. We 
find that blocking RHOA prenylation, by knocking out GGTase-I, markedly 
increases RHOA-GTP levels and activity, increases macrophage reverse cholesterol 
transport which markedly reduced atherosclerosis in GGTase-I knockout mice 
(131). Another study showed that blocking RHOA signaling by reduced prenylation 
triggered intestinal inflammation in intestinal epithelial cells isolated from 
inflammatory bowel disease patients (132). Furthermore, one study showed that 
inactivation of RHOA triggers production of mature IL-1β via activation of pyrin 
inflammasome (MEFV) in Hyper-IgD syndrome (HIDS) patients (133).  This 
overproduction of IL-1β is a major driving force for main pathological 
abnormalities in HIDS patients. As outlined in Paper 2, we believe the mechanism 
of hyperinflammation is related to RAC1 and not RHOA. Altogether these 
conflicting results needs clarification. On one hand active RHOA contributes 
regression of atherosclerosis, and on other side, inactivation of RHOA promotes 
inflammation in IBD and HIDS patients. These studies stresses the importance of 
exploring the biology of RHOA in specific tissues and cell types in more detail 
before proposing targeting RHOA or RHOA signaling in disease therapy. 
CDC42 
CDC42 is a ubiquitously expressed RHO family GTPase protein involved in the 
regulation of cytoskeleton remodeling and membrane trafficking that controls a 
wide range of physiological functions, including the formation of filopodia, cell 
motility, polarity, growth and cytokinesis (134, 135). Similar to RAC1, activated 
CDC42 is associated with several effectors, mainly PAK1, and IQGAP1. The 
majority of these effectors contain either a CDC42-RAC interacting (CRIB) domain 
or a p21-binding domain (PBD) in their structure that allows binding of 
CDC42GTP (136). Overexpression of CDC42 has been observed in lung cancer 
and melanoma, and this phenomenon is sometimes required for RAS-induced 
transformation (137). However, very few studies have described the role of CDC42 
in inflammation, particularly in endothelial cell-associated inflammatory diseases. 
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CDC42 is responsible for senescence-associated inflammation in endothelial cells, 
via activation of the p53/p21 pathway, and can thereby promote plaque formation 
in atherosclerosis in APOE–/– mice (138). In addition, CDC42 is required for 
promoting endothelial cell function and regeneration, which are important during 
vascular repair in acute lung injury and acute respiratory distress syndrome (139).   
IQ motif containing GTPase activating protein 1 (IQGAP1) 
IQGAP1 does not belong to a –CAAX protein family or RHO family, but it is the 
common effector for the RHO family proteins, most importantly RAC1, RHOA and 
CDC42. IQGAP1 is a 190 kDa ubiquitously expressed scaffolding protein that 
plays an important role in cytoskeletal rearrangement (140), the mitogen-activated 
protein kinase pathway (141, 142), and in β-catenin-mediated transcription (143). 
IQGAP1 is originally named due to its sequence containing isoleucine (I)-
glutamine (Q) domains (IQD) and a GTPase activation protein-related domain 
(GRD). In addition to that, it also contains a calponin homology domain (CHD), a 
coiled-coil domain (CCD), a tryptophan-tryptophan domain (WWD), and RAS 
GAP carboxyl-terminal domains (RGCTD). Several protein recognition motifs 
present in the multi-domain composition are responsible for wide array of IQGAP1 
interactions (144). Although the structure of IQGAP1 contains a GRD, it is unable 
to execute GTP hydrolysis; instead, it is thought to stabilize GTP-bound proteins 
(145-147).  
Even though IQGAP1 interacts with several proteins, no developmental or 
physiological defects were found in Iqgap1-knockout mice. The only phenotype 
observed was late-onset of gastric hyperplasia (148). Since IQGAP1 engages in 
interaction with multiple protein partners, it might be a clinically important target 
to combat diseases including cancer. For example, earlier studies reported that 
IQGAP1 is required for RAS-induced tumorigenesis via association with ERK1/2 
and phosphoinositol-3-kinase (PI3K), and thereby activating scaffold-induced 
MAPK pathways responsible for tumorigenesis (149, 150). Disrupting or blocking 
IQGAP1-ERK1/2 or IQGAP1-PI3K interactions is considered a promising strategy 
to inhibit tumor progression. Elevated levels of IQGAP1 has been noticed in many 
different cancers, and this facilitates the formation of complexes with the GTP-
bound forms of RAC1 and CDC42, which drive tumor progression (147). Earlier 
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studies reported that IQGAP1 is an attractive target against bacterial infections, 
because of the ability of bacteria to use IQGAP1 to modify cytoskeleton dynamics 
and form F-actin pedestals that are required for the entry of Salmonella 
typhimurium and Escheria Coli into the host cell (151-154). All of these results put 
together suggest that IQGAP1 is an attractive target to treat cancer, bacterial 
infections, asthma and several other diseases. 
When I began my studies, dogma held that prenylation is required for the membrane 
targeting or RHO family proteins and for the ability of RHO proteins to interact 
with GEFs, GAPs, and IQGAP1. In particular, the activation of RHO proteins was 
believed to require prenylation. However, some studies had shown, paradoxically, 
that statins, which reduce GGPP production, actually increases levels of GTP-
bound RHO proteins, but the mechanisms underlying this effect was not known. 
Statins 
Statins are potent inhibitors of the cholesterol biosynthesis pathway by reversibly 
inhibiting key regulatory enzyme HMG-CoA (3-Hydroxy-3-methylglutaryl-CoA) 
reductase (Figure 3) (155). Due to their structural resemblance to the HMG-CoA 
moiety, statins occupy the HMG-CoA binding site in the reductase enzyme (it has 
a higher affinity for binding than HMG-CoA) and thereby inhibit its enzymatic 
activity (155). Statins are one of the most widely-prescribed drugs in the world, and 
it is used primarily to reduce serum cholesterol levels in response to 
hypercholesterolemia and thereby reduce the risk of future cardiovascular disease 
(156).  Furthermore, statins possess some cholesterol-independent effects, also 
known as pleiotropic effects. These pleiotropic effects have in clinical trials been 
shown to be independent of cholesterol lowering and to include anti-inflammatory 
(157), antioxidant (158), anti-thrombogenic effects (159), and improved endothelial 
function effects (160).  Statin pleiotropic effects have been noted in several clinical 
trials: MIRACL (161), PROVE-IT (162) CARE (163), PRINCE (164), HPS (165) 
and ASCOT (166). In these clinical trials, statin-treated individuals had a reduced 
risk of heart disease and increased survival rate despite the fact that the statins did 
not reduce cholesterol levels in a significant fashion (167).  
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Fig 3: Biosynthesis of cholesterol and isoprenoid intermediates: Statins inhibit HMG-CoA 
reductase, a key enzyme in cholesterol biosynthesis regulation, by blocking synthesis of L-
mevalonate in the mevalonate pathway. L-Mevalonate is converted to isopentenyl pyrophosphate 
(Isopentenyl-PP) by mevalonate kinase and phosphomevalonate kinase, respectively. Isopentenyl 
pyrophosphate is subsequently converted to geranyl pyrophosphate (Geranyl-PP) and farnesyl 
pyrophosphate (Farnesyl-PP) by farnesyl diphosphate synthase. Furthermore, farnesyl-PP is 
converted to geranylgeranyl pyrophosphate (GGPP) by geranylgeranyl diphosphate synthase. 
Finally, geranylgeranyltransferase-I (GGTase-I) uses GGPP to initiate lipid modifications of CAAX 
family proteins. Statin therapy reduces the synthesis of GGPP and thereby inhibit lipid modifications 
of CAAX proteins.    
Several studies have cemented the view that pleiotropic statin effects—independent 
of cholesterol reduction—are mechanistically important. For example, statins 
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improve vascular endothelial function before significantly affecting serum 
cholesterol levels (160, 168, 169). The mechanism behind statins vasoprotective 
function is mainly due to the upregulation of endothelial nitrous oxide synthase 
activity (eNOS), which leads to increased synthesis and release of endothelial-
derived nitrous oxide (NO) (170, 171). These vasoprotective effects of statins are 
absent in eNOS–/– mice, which indicates that endothelial-derived nitrous oxide 
production mediates at least some parts of the beneficial effects of statins on 
endothelial function (172). The antioxidant effect of statins is another potential 
mechanism to restore endothelial cell function. Statins reduce the generation of 
ROS via down regulation of the angiotensin type1 (AT1) receptor and NAD(P)H 
oxidized subunit p22Phox (173).  
Some studies have reported that statins had a beneficial effect on other 
inflammatory diseases such as multiple sclerosis (MS), rheumatoid arthritis (RA) 
dementia, atherosclerosis, and systemic lupus erythematosus (SLE) (174-177). 
Statins reduce levels of high-sensitivity C-reactive protein (hs-CRP), a clinical 
marker for inflammation usually elevated in individuals with high cardiovascular 
risk (157, 178, 179). Most of the pleiotropic effects of statins are believed to be 
caused by reduced synthesis of the isoprenoid intermediates FPP and GGPP, which 
are used in the prenylation reactions (180) (Figure 1). Thus, statins are—in light of 
the aforementioned dogma—thought to prevent sub-cellular localization, 
membrane targeting, and activation of RHO family proteins. 
Until recently, several studies have reported on different pleiotropic effects of 
statins. Many of the pleiotropic effects observed in cell cultures were restored by 
adding of GGPP to the culture medium but not by adding FPP or LDL-cholesterol, 
suggesting that geranylgeranylation of RHO proteins, such as RAC1 and RHOA 
underlies the effects. One example of this is the statin-induced vasoprotective 
effects, which are reversed by addition of GGPP but not FPP or ox-LDL, suggesting 
that inhibition of geranylgeranylation of RHO proteins is responsible for the 
vasoprotective mechanisms (171, 181, 182). However, geranylgeranylation is also 
important for a large class of RAB proteins, which are prenylated by GGTase-II in 
a pathway that is entirely distinct from that mediated by GGTase-I. RAB proteins 
coat membranes of vesicles and are important for their correct targeting within the 
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cell. These findings indicate that RHO proteins or RAB proteins might be involved 
in mediating the beneficial effects of statin treatment.  
However, despite having these beneficial side effects, statins can also cause some 
serious complications. A large proportion of statin-treated patients experience some 
form of muscle pain (myalgia) symptoms, which can range from mild to severe. In 
severe cases statins can cause rhabdomyolysis, which has been reported to occur in 
0.44-0.54 cases per 10 000 person-years. Rhabdomyolysis is a disease in which 
skeletal muscle starts to break down, which in turn can cause kidney failure and 
death (95, 96). Cerivastatin was the first drug to be discontinued in the United States 
due to high rates of fatal rhabdomyolysis (183). The exact cause of statin induced 
myalgia and rhabdomyolysis remains elusive, but in light of findings in our group, 
we have hypothesized that statin-induced inhibition of prenylation of RHO family 
GTPases underlies both positive and negative pleiotropic effects. 
Targeting GGTase-I in diseases 
Cancer  
RAS is one of the most well-studied oncogenes and is a notorious driver of 
progression in as much as 30% human cancers. Direct targeting of RAS has been 
extremely difficult due to its high affinity for the active GTP-bound state and the 
structural similarities with other GTPase proteins (184).  Thus a strategy developed 
to use FTIs to combat RAS-induced cancers. As outlined earlier, clinical trials with 
FTIs failed due to alternative prenylation of KRAS and NRAS. GGTase-I inhibitors 
in combination with FTIs could have been an effective strategy but researchers 
tested GGTIs and also dual-prenylation inhibitors as potential anti-cancer drugs 
(185).  In our lab, we have earlier shown that knockout of both FTase and GGTase-
I completely blocked KRAS prenylation, rendered the protein soluble, and 
incapable of causing cancer (30). So far one GGTI (GGTI-248) went through 
clinical trials (26). But overall, the strategy of targeting both prenyltransferases in 
cancer therapy is likely to be too toxic as no cells can proliferate in the absence of 
these enzymes. Some cells clearly survive in the absence of both enzymes, such as 
macrophages and type II pneumocytes in the lung (29). 
 
 17 
 
Inflammation 
Explaining the importance of prenylation in the development of inflammatory 
diseases is particularly complicated due to a surprising discovery in our group. 
According to current dogma, one would expect that blocking prenylation would 
inhibit RHO protein activity and that this, in turn, would protect against 
inflammatory symptoms caused by RHO protein signaling. Surprisingly, however, 
we found that knockout of GGTase-I in macrophages hyperactivates RHO proteins, 
stimulates pro-inflammatory signaling pathways, enhances cytokine production in 
response to lipopolysaccharide (LPS) stimulation, and causes mice to develop 
severe erosive arthritis in all of their joints (48). This result not only challenges the 
long-held assumption that prenylation is required for CAAX protein function but 
suggests that prenylation might a negative regulator of RHO-GTPase activation. 
Furthermore, our lab showed that knockout of GGTase-I in macrophages increases 
active RHOA and that this mediates an increase in reverse cholesterol transport and 
a 60% reduction in atherosclerosis in LDL receptor-deficient mice (131). These 
discoveries not only challenge the widely-held view that prenylation is required for 
activation but they also shed light on the paradoxical findings of increased GTP-
loading and cytokine production in statin-treated cells and provides an impetus for 
studying this further. How do RHO family proteins become GTP-bound when they 
are not prenylated? Which GGTase-I substrate drives inflammation in GGTase-I-
deficient mice? Or are other mechanisms in place? What is the importance of RHO 
protein prenylation? There are many questions that need answers. 
The current thesis focuses on defining the importance of GGTase-I in macrophage-
induced innate immunity. Macrophages are crucial mediators for immune sensing. 
Macrophages migrate into damaged tissues and recruit other inflammatory cells, 
trigger inflammatory cytokine production, generate ROS, contribute to 
phagocytosis, pathogen killing, and remove apoptotic cells from the site of infection 
(186). These events altogether contribute to primary defence mechanisms for 
humans via unleashing a wide range of innate immune responses against infections 
(186). All these immune responses are responsible for controlling the signalling 
events of inflammation.   
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Innate immune system 
The innate immune system is a first-line defence mechanism that protects the host 
from pathogens such as fungi, bacteria, and insects. The primary function of the 
innate immune system is to recruit immune cells to the site of infection. This results 
in the release of chemical mediators such as pro- and anti-inflammatory cytokines, 
activation of the complement cascade, and formation of antibody complexes. These 
factors contribute to a proper and well-balanced immune response against harmful 
pathogens (187). 
Inflammation is a key protective mechanism in innate immune response driven by 
the recruitment of immune cells at the site of infection by harmful pathogens. Well-
controlled inflammation protects the host from infection. However, a less well-
controlled response, in particular an excessive one, is at the root of many chronic 
inflammatory and autoimmune diseases. Immune cells contain a special group of 
receptors on their cell membranes called pathogen recognized receptors (PRRs). 
The amount of innate immune response depends primarily on how fast the PRRs 
recognize pathogen-associated molecular patterns (PAMPs) generated in response 
to harmful pathogens and also how fast he PRRs recognize danger-associated 
molecular patterns (DAMPs) which generated in response to endogenous host stress 
(188). Activation of PRRs stimulates inflammatory signaling cascades that result in 
the production and secretion of chemical mediators such as interferons, pro-
inflammatory and anti-inflammatory cytokines (189). 
The inflammasome is a multi-domain complex which contains one or more 
caspases in their structure, and it is essential for the activation of inflammatory 
responses. Inflammasomes are expressed mainly in myeloid cells and act as 
immune sensors (receptors) controlling the activation of caspase-1 that further 
results in the production of the highly immune-active cytokines IL-1β and IL-18.  
To date, researchers have identified five receptors responsible for inflammasome 
formation. They are NACHT, LRR and PYD domains-containing protein 1 
(NLRP1), NLRP3, NLR family CARD domain-containing protein 4 (NLRC4), 
absent in melanoma 2 (AIM2) and pyrin (MEFV) (190). Activation of 
inflammasome is a key event, mediated by innate immune response and; in the 
progression of several auto-inflammatory diseases (191). Interleukin-1 beta (IL-1β) 
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is an important inflammatory cytokine expressed in myeloid cells like macrophages 
and monocytes at the site of infection or injury.  
Many cells produced IL-1β in response to bacterial toxins (lipopolysaccharide) via 
TLR4 signaling pathway. But, LPS alone is not enough to stimulate activation and 
release of IL-1β (192). These results led to emergence of two signal model for 
maturation and release of IL-1β in cells. In Signal I, LPS stimulate the synthesis of 
pro-IL-1β, whereas signal II is required for conversion of pro-IL1beta to its active 
form (P17). The exact mechanism for signal II is not clearly understood but earlier 
research shown that second signal mediated through activation of caspase-1 (193).  
This cytokine, and also IL-18, is secreted via a non-classical secretory pathway that 
doesn’t involve the ER-golgi-plasma membrane vesicular transport machinery 
(194). Several bacterial toxins (e.g. lipopolysaccharide, LPS) can activate caspase-
1 mediated signaling that triggers production of active IL-1β (195). Recent studies 
showed that activation of RHOA in response to bacterial toxins is essential to inhibit 
caspase-I mediated pyrin (one of the components of the inflammasome, MEFV) 
inflammasome signaling in macrophages (196).  
Rheumatoid arthritis (RA) 
RA is a chronic inflammatory autoimmune disease caused by progressive 
destruction of joints in the body (Fig. 4). RA is believed to originate from losing 
self-tolerance against immunogens which leads to inappropriate activation of 
immune reactions that affect structural cells and building blocks of bone, cartilage, 
and connective tissue in the joints (197, 198). RA is characterized by severe pain, 
stiffness and swelling of joints. RA affects 1% of the population globally, but the 
exact cause of RA remains unclear (199). Earlier studies reported that formation of 
immune complexes that activate immune cells, production of self-reactive 
antibodies (anti-citrullinated protein antibodies and C-reactive protein antibodies), 
infiltration of immune cells (lymphocytes and macrophages) into the synovium are 
key regulatory events that underlie the initiation and progression of disease (200). 
These effects lead to the aggressive development of synovium hyperplasia and 
subsequent damage of cartilage present in periarticular bone. Synovium is a single 
thin translucent membrane layer present in non-articular surfaces of the joint but, 
during RA, immune cells infiltrate inside the joint cavity, form immune complexes 
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to activate immune cells to produce cytokines, self-reactive antibodies and matrix 
metalloproteases (MMPs), causing the synovium to expand and this process goes 
hand-in-hand with to joint destruction (198).  
    
Fig 4: Photos of normal mouse joint and joint from mouse with arthritis: Hematoxylin and 
Eosin–stained sections of joints from 12-week-old mice. S, synovium;B, bone. Note thickened 
synovium in the square at right. 
 
Among lymphocytes, T-lymphocytes, particularly, CD4+, CD8+ and effector T-
lymphocytes are involved in the pathogenesis of RA (201). CD4+ T-lymphocytes 
also called regulatory T-lymphocytes (Tregs), help to maintain self-tolerance by 
inhibiting pathological immune responses against immunogens (201). Defects in 
Tregs are often noticed in RA patients. Tregs isolated from RA patients produce 
high levels of inflammatory cytokines and suppress proliferation of effector T-
lymphocytes that are responsible for the production of anti-inflammatory cytokines 
like TGF-β and IL-10 (202).  Earlier studies found evidence that depletion of CD4+ 
T cells reduced the severity of disease in peptidoglycan aggrecan (PG)-immunized 
mouse model (203). 
Further evidence came from multiple studies showing that CD4+ T-lymphocytes 
form complexes with aggressive forms of disease-contributing proteins encoded by 
Hla-drb1, a gene involved in the progression of inherited arthritis (204). Hla-drb1 
encodes proteins that are components of human leukocyte antigen-DR1 (HLA-
DR1). HLA-DR1 is expressed by antigen-presenting cells (APCs) such as 
macrophages and acts as a ligand to activate CD4+ T-lymphocytes and thereby 
trigger wide array of inflammatory responses (204). Several clinical studies 
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reported that targeting T-lymphocytes and their products have shown significant 
benefit in treating RA (205-207). 
Monocytes/Macrophages also play a central role in the pathogenesis of RA. 
Typically, monocytes in blood infiltrate into the synovial membrane and 
differentiate into macrophages that increase the production of inflammatory 
mediators. The hypersecretion of inflammatory mediators such as cytokines and 
MMPs, leads to the destruction of extracellular matrix proteins which breaks down 
vital joint components. Earlier studies have shown that a population of CD4+CD25+ 
monocytes is elevated in RA patients (208). Also, activated monocytes promote 
bone resorption by differentiating into osteoclasts, which are only cells in the body 
that can perform the task of bone resorption (209). Depletion of monocyte 
populations has shown great benefit in treating inflammation in mice (210, 211). 
Macrophages act as APCs and present immunogenic peptides to CD4+ T-
lymphocytes to activate them and then trigger inflammatory responses as described 
above. In addition to that, earlier studies showed that ROS produced by 
macrophages and neutrophils contribute to cartilage destruction. ROS also 
promotes signaling pathways that contribute to inflammation (212). 
There is no curative therapy for RA patients. Current therapies and drugs are mainly 
focused on reducing cytokine productions to alleviate joint pain but not on reversing 
cartilage function. This is a problem that needs further research to find better 
molecular targets or predictive biomarkers that can lead to treatment at an earlier 
stage to more effectively combat the disease. 
Mevalonate kinase deficiency (MKD) 
Mevalonate pathway—synonymous with the cholesterol biosynthetic pathway— is 
a key metabolic pathway responsible for the synthesis of cholesterol (180). 
Inhibiting the first step of this pathway with statins leads to reduced production of 
cholesterol. A few steps down in the pathway is where mevalonate kinase (MK) 
operates. MK is responsible for conversion of mevalonate to phosphomevalonate 
(180). Patients carrying loss of function mutations in the gene encoding the MK 
enzyme are prone to developing a host of inflammatory phenotypes including 
recurrent fever attacks, lymphadenopathy, arthralgia, skin lesions, and diarrhoea 
(213). Hyperimmunoglobulinemia D syndrome (HIDS), and mevalonate aciduria 
 22 
 
(MA) are two rare hereditary diseases that occur due to the deficiency of MK (213). 
Collectively these disorders are called MK deficiency (MKD). Until now, less than 
300 MKD cases have been detected globally (214). Increased serum levels of 
Immunoglobulin D (IgD), and increased excretion of mevalonate serve as specific 
biomarkers to identify MKD. In addition, increased levels of inflammatory markers 
such as C-reactive protein (CRP) and serum amyloid A (SAA) can frequently be 
detected in the patient's serum (215). Current therapies available for MKD patients 
are mainly focused on reducing IL-1β levels using IL-1β receptor antagonists such 
as Anakinra (216). However, what are the precise mechanisms underlying this 
disease?  
Excessive production of IL-1β is a dominant force in the progression of MKD. 
Activation of NFβ signaling is mainly involved in the production of IL-1β in MKD 
monocytes, and the conversion of pro-IL-1β to mature IL-1β is carried out via the 
inflammasome-dependent activation of caspase-1 (217). The exact molecular 
mechanisms for the development of inflammatory phenotypes are not clearly 
understood. However, it is thought that reduction of prenylation of RHO family 
proteins is involved in the development of MKD cellular phenotypes. This is 
because MKD leads not only to reduce cholesterol synthesis but also to the reduce 
production of GGPP and FPP. Moreover, incubating macrophages with statins—to 
inhibit HMG-CoA reductase upstream of MK—recapitulates the in vitro cellular 
phenotype observed in monocytes of MKD patients (218). The same study showed 
that aberrant signaling of RAC1 causes caspase-1 dependent maturation of IL-1β 
production (218). Importantly, targeting RAC1 blunts cytokine production induced 
by statins (218). In support of the notion that these effects are caused by reduced 
prenylation, the increased IL-1β production was rescued by addition of GGPP. The 
rescue of increased cytokine production with GGPP suggests that defective RHO 
protein prenylation might be involved in the progression of MKD (219, 220). Some 
studies report that increased caspase-1-dependent IL-1β production was due to 
inactivation of RHOA signaling by statins (221). However, researchers failed to 
address how increased RAC1 activation and inactivation of RHOA communicated 
with each other in the development of MKD. 
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Until now, no studies have proposed a convincing model for how statins and MKD 
leads to increased cytokine production. And many other questions remain: Why do 
mice lacking GGTase-I in macrophages develop hyperinflammation and arthritis? 
Why do RHO family proteins become GTP-bound in cells with inhibited GGTase-
I or cells treated with statins? Is one or many of GGTase-I’s 60+ substrates involved 
in arthritis development? In this thesis I have addressed these questions and 
provided clear answers to a few of them. 
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3 EXPERIMENTAL STRATEGY 
In this section, I describe the transgenic mouse models that were used to uncover 
the cellular and molecular mechanisms behind the hyperinflammation and erosive 
arthritis in mice lacking GGTase-I in macrophages. I will also provide a rationale 
for the use of mice in research and describe techniques used to manipulate its genes. 
Transgenic Mice 
The mouse (Mus musculus) is one of the most popular biomedical research tools 
that has been used to understand both basic biology and pathogenesis of human 
diseases. This due to the close similarity between mice and humans in terms of 
molecular behaviour compared to other model systems, e.g. rats and flies (222). The 
main reasons for using mouse models include anatomy and physiology similarity 
to humans, easy handling, short breeding cycle (three weeks) and early sexual 
maturity (five weeks) (223, 224). From the last three decades, the use of mouse 
models has dramatically increased due to the emergence of recombinant DNA 
technology. Advances in the field have given researchers more opportunities to 
introduce foreign DNA elements (transgene) into the mouse genome (225). These 
transgenic mice give us sophisticated tools to study the effect of deletions or 
mutations of specific genes in the whole mouse or in specific tissues and the 
opportunity to evaluate their role in health and disease development. For example, 
mice lacking low-density lipoprotein receptor (LDLr) are used to study the 
development of atherosclerosis (226). A common way to generate transgenic mice 
is by pronuclear microinjection of a transgene into the zygote. Unfortunately, the 
method has an increased risk of random incorporation of foreign DNA elements 
into the host genome. To overcome that, a method based on the targeted 
manipulation of embryonic stem cells (ESCs) to more reliably produce transgenics 
with correct insertions/substitutions. In this method, the transgene is inserted by 
homologous recombination into a specific locus of a predetermined target DNA 
region. Upon successful integration, the manipulated ESCs are injected into 
blastocysts, and the embryos are implanted into a pseudopregnant female. The 
resulting pups are called chimaeras. This particular method allows us to delete or 
inactivate the desired gene, i.e., create a knockout (225). 
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Cre-loxP techniques 
The Cre-LoxP technique allows for the excision of an engineered DNA sequence 
from genomic DNA. This tool uses Cre recombinase, an enzyme derived from P1 
bacteriophages that recognises loxP sites present in the inserted engineered DNA. 
P1 plasmids contain sequences called loxP (locus of X-over P1 bacteriophage), 
consisting of a 34-bp DNA sequence, that includes 13 symmetric base pair 
sequences in both ends and 8 asymmetric base pairs sequences at the center. The 
Cre recombinase identifies an engineered sequence that is flanked by loxP sites (this 
sequence is chosen to be an essential or important part of the activity of target gene) 
and executes excision of DNA sequence between the loxP sites (Fig. 5) (227).  
 
Fig. 5. Critical DNA sequence, which is vital for target gene activity was flanked by LoxP sites. 
Cre recombinase recognize and then bind to the LoxP sites. Once Cre recombinase binds to LoxP 
sites, it cuts out the target gene sequence present between the LoxP sites resulting in inactivation of 
the target gene. 
There are several ways to express Cre recombinase in cells. First, it is common to 
simply transfect a plasmid encoding the recombinase, another way is by using a 
virus to introduce Cre recombinase in cells or animals, and a third is to engineer 
transgenic mice harbouring Cre recombinase driven by a specific promoter (228, 
229). This promoter is expressed in either ubiquitously or is constrained to a specific 
cell type/tissue. The main advantage of using these mouse models is the ability to 
recapitulate human disease conditions in mice by introducing transgene mutations 
and thus find targets that are responsible for disease progression. For example, mice 
expressing mutant KRASG12D are used to study the development of different 
cancers including lung, skin and pancreatic cancers (230).   
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In the present study, we used the Cre-loxP technique to inactivate GGTase-I, RAC1, 
RHOA and CDC42 in mice macrophages; and we used a conventional 
knockout/null allele for IQGAP1. 
Macrophage-specific knockout of GGTase-I and RHO proteins 
To generate a macrophage-specific knockout mouse for GGTase-I (Pggt1bΔ/Δ), we 
first generated a conditional Pggt1b allele (Pggt1bfl/fl) by inserting loxP sites 
flanking exon 7. Exon 7 encodes amino acids that are essential for the catalytic 
activity of the beta subunit of GGTase-I. The Pggt1bfl/fl mice were bred with 
transgenic mice expressing Cre recombinase under the control of Lysozyme-M-
promoter (LysM-Cre). The resultant heterozygous offspring lack 50% GGTase-I 
activity in myeloid cells, which is enough to effectively prenylate RHO family 
proteins in myeloid cells (heterozygous GGTase-I knockout mice are 
indistinguishable from WT). We further intercrossed these mice to get 100% 
deletion of GGTase-I in macrophages. These mice were termed as Pggt1bΔ/Δ mice 
(30) (= D = deleted) 
In Paper I, using these mice, we studied general cellular and molecular mechanisms 
underlying inflammation in Pggt1bΔ/Δ mice and found that GGTase-I-deficiency 
activates the pyrin inflammasome, caspase-1, and IL-1 production.  
In Paper II, we studied the hypothesis that one of the main GGTase-I targets RAC1, 
RHOA, and CDC42 become hyperactivated in the absence of prenylation and 
underlie the increased cytokine production in vitro and arthritis in vivo in Pggt1bΔ/Δ 
mice (mice harbouring conditional knockout alleles for Rac1 (231), Rhoa (232) and 
Cdc42 (233) were generated as described). To accomplish this, we knocked out one 
copy of Rac1, Rhoa or Cdc42 genes in Pggt1bΔ/Δ mice in the same way we 
generated Pggt1bΔ/Δ mice (Figure 6). These mice were designated 
Rac1Δ/+Pggt1bΔ/Δ, RhoaΔ/+Pggt1bΔ/Δ, and Cdc42Δ/+Pggt1bΔ/Δ. We also evaluated 
mechanisms underlying the accumulation of RAC1, RHOA, and CDC42 in the 
active GTP-bound state in Pggt1bΔ/Δ macrophages. As outlined in Paper II, we 
found that non-prenylated RAC1 binds strongly to IQGAP1. We also tested the role 
of IQGAP1 in the increased inflammation in Pggt1bΔ/Δ mice. For that, we knocked 
out of IQGAP1 (Iqgap1–/–) (148) by breeding Iqgap1–/– mice with Pggt1bΔ/Δ mice. 
These mice were designated Iqgap1–/–Pggt1bΔ/Δ (Fig. 6). 
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Fig. 6. Generation of macrophage-specific knockout of GGTase-I and RhoGTPases in mice. 
 28 
 
4 BACKGROUND AND PREVIOUS RESULTS 
Several studies have reported that RHO family proteins are important for tumor cell 
metastasis, so targeting RHO family proteins has been considered a potential 
strategy to treat cancer. Furthermore, some studies have found that RHO family 
proteins, most importantly RAC1, RHOA, and CDC42 are important for immune 
cells to perform their functions (234, 235). RHO family proteins are important in 
innate immunity functions such as the response to bacterial toxins.  
As outlined earlier, RHO family proteins are substrates of GGTase-I during their 
maturation process, and geranylgeranylation has been widely assumed to be 
essential for RHO-protein activity. Therefore, targeting GGTase-I, to prevent 
prenylation of RHO proteins, has been proposed as a potential strategy to treat 
inflammatory diseases such as atherosclerosis and multiple sclerosis (236). To 
evaluate this hypothesis, our lab has mice with a conditional knockout allele for 
Pggt1b, the gene encoding the essential beta-subunit of GGTase-I, and then 
inactivated the enzyme in macrophages (48). 
The knockout of macrophage GGTase-I clearly blocked the prenylation of RHO 
family proteins. However, contrary to expectations, the mice developed severe, 
spontaneous, and chronic joint inflammation, which resembles erosive arthritis in 
humans (Fig. 7A) (48). Even more surprisingly, GGTase-I-deficient macrophages 
had increased levels of RHO proteins in their active GTP-bound form compared to 
controls (Fig. 7B), and they also produced higher amounts of pro-inflammatory 
cytokines, such as IL-1β, IL-6, and TNF-α (Fig. 7C). Moreover, non-prenylated 
RAC1 still interacted well with the plasma membrane. Inhibition of RAC1 
signaling with a small-molecule inhibitor or knocking down RAC1 expression with 
shRNAs in GGTase-I-deficient macrophages reduced the secretion of pro-
inflammatory cytokines. These results suggest the interesting but at the time 
farfetched, possibility that a single GGTase-I substrate (out of many dozens) may 
be responsible for the inflammatory phenotype. But we had not performed similar 
experiments with RHOA and CDC42. 
 29 
 
 
Fig. 7. Knockout of GGTase-I results in erosive arthritis in mice. (A). Synovitis (S) and Erosion 
(E) in bone metatarsal joint inflammation in control and knockout mice. (B). Accumulation of GTP-
bound form of non-prenylated RHO proteins in GGTase-I knock macrophages. (C). Increased 
production of inflammatory cytokine IL-1β, IL-6 and TNF-α in response to LPS in knockout 
macrophages and wild-type control macrophages treated with GGTI-298.    
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5 AIMS 
Our long-term goals are to define the biochemical and medical importance of the 
posttranslational processing of CAAX proteins. The aim of my PhD thesis was to 
define cellular and molecular mechanisms underlying inflammation and arthritis in 
mice lacking GGTase-I in macrophages. 
Specific Aims 
Project I: To define the molecular mechanisms involved in the excessive innate 
immune responses of GGTase-I-knockout macrophages. 
Project II: To test the hypothesis that RAC1, RHOA, or CDC42 is responsible for 
inflammation and arthritis in GGTase-I knockout mice, and to define the 
mechanism behind the increased GTP-loading of non-prenylated RHO family 
proteins.  
Knockout of GGTase-I in mouse macrophages causes inflammation and erosive 
arthritis. GGTase-I-deficient macrophages contain increased levels of RHO 
proteins in their active GTP-bound form, and they secreted higher amounts of pro-
inflammatory cytokines in two different pathways: an NFB-mediated pathway 
resulting in IL-6 and TNF secretion, and an inflammasome-mediated pathway 
resulting in IL-1maturation. However, there are many gaps in our understanding 
of the biochemical and physiologic consequences of blocking prenylation. For 
example, is the increased signaling triggered by specific Toll-like receptors (TLR)? 
Which pathways are essential for the pro-inflammatory responses? Is the 
inflammasome activated in Pggt1bΔ/Δ macrophages and if so, which part? By what 
mechanism does non-prenylated RHO proteins become constitutively GTP bound? 
In my PhD studies, I have addressed these questions and present the results in two 
manuscripts. 
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6 SUMMARY OF RESULTS 
Project I 
To define the molecular mechanisms involved in the excessive innate immune 
responses of GGTase-I-knockout macrophages (237). 
Pggt1b is important for cytokine production in macrophages 
 
Fig. 8. Knockout of Pggt1b altered the balance between inflammatory and anti-inflammatory 
cytokine production. (A―D) Semi-quantification of IL-1β, TNF-α, IFN-1β, IL-10 cytokines by 
ELISA shows in control and GGTase-I knockout macrophages supernatants stimulated with TLR 
ligands for 8 h. Data are from three different experiments.  
Toll-like receptors (TLRs), a class of pattern recognition receptors (PRRs), detect 
and mount responses to pathogen-associated molecular patterns (PAMPs) that are 
generated by invading pathogens at a site of infection (238). To find out more about 
the role of Pggt1b in the regulation of TLR-induced cytokine production, we 
incubated bone marrow-derived macrophages with the TLR4-agonist 
lipopolysaccharide (LPS), TLR9-agonist CpG, TLR2-agonist Pam3CSK4, TLR3-
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agonist poly (I:C), and TLR7-agonist R848. Pggt1bΔ/Δ macrophages showed 
increased production of pro-inflammatory cytokines (Fig. 8A & 8B) and reduced 
production of anti-inflammatory cytokines in response to TLR agonists (Fig. 8C & 
8D). Altered balance between pro-inflammatory and anti-inflammatory cytokines 
in Pggt1bΔ/Δ macrophages suggests that GGTase-I has a central role in the 
regulation of cytokine production. 
Pggt1b is important for activation of PI(3)K signaling in macrophages 
 
 
Fig. 9. Knockout of Pggt1b reduced signaling of the PI3K-AKT-GSK3β pathway. Western blot 
analysis of phospho-AKTS473, phospho-GSK3β, phospho-RELAS536, phospho-c-junT239 and p70-
S6K in bone marrow-derived macrophages stimulated with LPS (10 ng/ml) for 0, 5, 10, 15, 30, 60 
and 120 Min. 
Next, we investigated which signalling pathway was responsible for the altered 
balance of cytokine production in Pggt1bΔ/Δ macrophages. Pggt1bΔ/Δ macrophages 
exhibited the reduced activity of pAKTS473 and increased the activity of GSK3β in 
response to LPS treatment compared to the controls used in this project. Two well-
known targets of GSK3β, RELA and c-JUN, had increased levels of phosphorylated 
S536 and Thr239 respectively in Pggt1bΔ/Δ macrophages, which further confirms 
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increased GSK3β activity (Fig. 9). Furthermore, reduced activity of P70S6K, one 
important downstream target of mTORC1 (Fig. 9), suggests that GGTase-I controls 
the signaling of the mTORC1-pAKT-GSK3β pathway or the PI3K-AKT pathway. 
Pggt1b enzyme increases association of KRAS and P110δ and thereby controls 
cytokine productions 
 
 
Fig. 10. Knockout of Pggt1b increased KRAS-p110δ dissociation and thereby increased 
inflammatory cytokine production. (A) IL1β ELISA levels from control and Pi3kcd–/– macrophage 
supernatants after stimulation with different concentrations of LPS for 8hrs. (B). ELISA levels of 
IL1β from the macrophages after transfection with active p100δ, p110wt and Pggt1b in Pggt1bΔ/Δ 
macrophages. (C). Immunoblots showing interaction levels of KRAS with different PI3K catalytic 
subunits from the lysates collected from macrophages after stimulation with LPS for 0, 5, 10, 15 and 
30 min. NS (not significant), **** P < 0.0001. 
As stated above, Pggt1bΔ/Δ macrophages showed deregulation of PI(3)K-AKT-
GSK3β pathway in response to LPS treatment. Recent results have shown that 
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inactivation of p110δ, a class-1 PI3K catalytic subunit, makes mice more prone to 
LPS-induced endotoxin death (239). Moreover, Pik3cd–/– (p110δ knockout) 
macrophages produced more IL-1β (Fig. 10A), which pheno-copied Pggt1bΔ/Δ 
macrophages. Forced expression of active p110δ in Pggt1b knockout macrophages 
normalized the levels of pro-inflammatory cytokine secretion, suggesting that 
deregulation of p110δ signaling contributes to the inflammatory cytokine 
production (Fig. 10B). We found a disturbance in the interaction between KRAS 
and P110δ (Fig. 10C) in Pggt1bΔ/Δ macrophages. LPS stimulation made this 
interaction stronger for a short time (5 min), but the effect is not sustained for a 
longer period. 
Pyrin (MEFV) is responsible for the increased inflammasome in Pggt1b 
knockout macrophages  
 
Fig. 11. Knockout of Pggt1b caused increased activation of the pyrin-dependent 
inflammasome. (A) Immunoblot analysis for mature IL-1β and Caspase-1 in supernatants, and pro-
IL-1β and pro-Caspase-1 in lysates of LPS-stimulated BM macrophages. (B) Immunoblot analysis 
for mature IL-1β and Caspase-1 in supernatants, and pro-IL-1β and pro-Caspase-1 in lysates of 
macrophages incubated with siRNAs targeted against Aim2, Mefv and Nlrc4. 
Many of the inflammatory cytokines are regulated through inflammasome activity 
by activating caspase1 signaling (240). We therefore examined the role of 
inflammasome activation in Pggt1bΔ/Δ macrophages in response to LPS. Increase 
in inflammasome activity contributes to the production of more IL-1β cytokines. 
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Pggt1bΔ/Δ macrophages produced more active IL-1β and had increased activation 
of caspase-1 signaling, which indicates that caspase-1 is important for active IL-1β 
production in the GGTase-I-deficient cells (Fig. 11A). We further examined which 
inflammasome receptor responsible for the increased caspase1 activity in Pggt1bΔ/Δ 
macrophages. We found that knockdown of pyrin (Mefv) but not Aim2 and Nlrc4 
in Pggt1bΔ/Δ macrophages reduced IL-1β production and Caspase-1 signaling (Fig. 
11B).   
Conclusion 
Knockout of GGTase-I results in an impaired PI3K signaling pathway that caused 
increased inflammatory signaling in macrophages. Impaired PI3K signaling 
contributed to the increased production of inflammatory cytokines and increased 
activation of pyrin-dependent inflammasome signaling in Pggt1bΔ/Δ macrophages. 
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Project II 
To test the hypothesis that RAC1, RHOA, or CDC42 is responsible for 
inflammation and arthritis in GGTase-I knockout mice, and to define the 
mechanism behind the increased GTP-loading of non-prenylated RHO family 
proteins (Submitted manuscript).  
RAC1 mediated erosive arthritis in Pggt1bΔ/Δ mice (Manuscript) 
 
Fig. 12. Knockout of RAC1 in Pggt1bΔ/Δ mice reduced erosive arthritis, inflammasome 
activation and inflammatory cytokine production. (A―B) Synovitis and erosion scores from 
joints of Pggt1bΔ/+ (n = 4), Pggt1bΔ/Δ (n = 12), and Rac1Δ/+ Pggt1bΔ/Δ (n = 9) mice at 12 week age. 
(C) Immunoblots showing levels of mature IL-1β and Caspase-1 in supernatants (Sup), and pro-IL-
1β and pro-Caspase-1 in lysates (Lys) of LPS-stimulated BM macrophages; Beta-Tubulin was used 
as a loading control. Nigericin (NGR) was used as a positive control to induce inflammasome-
mediated Caspase-1 activation and IL-1β production. (D) ELISA cytokine levels of IL-1β, IL-6 and 
TNF-α on bone marrow-derived macrophage supernatants from Pggt1bΔ/+ (n = 3), Pggt1bΔ/Δ (n = 
4) and Rac1Δ/+ Pggt1bΔ/Δ (n = 3). n.s not significant, ** P < 0.01, *** P < 0.001. 
Next, we examined the role of three CAAX proteins in the development of arthritis 
in Pggt1bΔ/Δ mice. For that, we knocked out one copy of Rac1 (Rac1Δ/+Pggt1bΔ/Δ), 
one copy of Rhoa (RhoAΔ/+Pggt1bΔ/Δ) and one copy of Cdc42 (Cdc42Δ/+Pggt1bΔ/Δ) 
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in Pggt1bΔ/Δ mice. Histological analysis on joints revealed that knocking out of one 
copy Rac1 reduced synovitis and erosion scores in Pggt1bΔ/Δ mice at 12 weeks age 
(Fig. 12A & 12B). 
We further asked whether knocking out one copy of Rac1 was enough to reduce 
caspase-1 mediated mature IL-1β production in the absence of Pggt1b in 
macrophages (Fig. 12C). Deletion of one copy of RAC1 significantly reduced the 
production of pro-inflammatory cytokines such as IL-1β, TNF-α and IL-6 (Fig. 
12D) in Pggt1bΔ/Δ macrophages in response to LPS, while knocking out one copy 
Rhoa and Cdc42 did not have any effect on cytokine secretion. From the above 
results, we conclude that RAC1 mediates the production of cytokines which lead to 
the development of erosive arthritis in Pggt1bΔ/Δ mice. 
Non-prenylated RAC1 bound strongly to IQGAP1 which contributed to GTP 
loading and inflammatory signaling 
            
Fig. 13. Non-prenylated RAC1 associated strongly with IQGAP1 and contributed to TLR-
induced pro-inflammatory cytokine secretion. (A) Immunoprecipitation analysis showing RAC1 
interaction with IQGAP1 in Pggt1bΔ/+ and Pggt1bΔ/Δ macrophage lysates. (B) Synovitis and erosion 
scores from joints of the Pggt1bΔ/+ (n = 4), Pggt1bΔ/Δ (n = 9), Iqgap1–/– Pggt1bΔ/Δ (n = 7) mice at 
12 weeks of age. (C) Immunoblots showing levels of RAC1-GTP, RAC1, IQGAP1 from Pggt1bΔ//+ 
and Pggt1bΔ/Δ and Iqgap1–/– Pggt1bΔ/Δ macrophage lysates. Actin was used as loading control, and 
np-RAP1 was used as a marker for the absence of GGTase-I. (D)  IL-1β, IL-6 and TNFα cytokine 
levels in supernatants of bone marrow-derived macrophages from Pggt1bΔ/+ (n = 3), Pggt1bΔ/Δ (n = 
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3) and Iqgap1–/– Pggt1bΔ/Δ (n = 3) mice after stimulation with LPS (10ng/ml) for 8 hrs.  * P < 0.05, 
** P < 0.01, *** P < 0.001. 
Next, we investigated possible reasons for the conversion of non-prenylated RAC1 
into its active GTP-bound form in Pggt1bΔ/Δ macrophages. In order to do so, we 
used mass spectroscopy to find RAC1-specific GAPs in GGTase-I knockout 
macrophages. We identified a list of 717 proteins, whose levels were significantly 
different in GGTase-I knockout macrophages compared to control macrophages 
(Table 3). Out of 717 proteins, five of them were specific GAPs for RAC1 and the 
top hit was RAS GTPase activating-like protein 1 (IQGAP1). Instead of exhibiting 
conventional GAP activity, IQGAP1 is known to stabilize RAC1 in its GTP-bound 
conformation. We further corroborated this finding with IP-western blots and found 
an increased association between non-prenylated RAC1 and IQGAP1 (Fig. 13A).  
To determine the role of IQGAP1 in inflammation, we knocked out Iqgap1 in 
GGTase-I knockout mice. Knockout of Iqgap1 markedly reduced inflammation in 
mouse joints (Fig. 13B), and essentially normalized the levels of RAC1-GTP (Fig. 
13C) along with a significant reduction of inflammatory cytokine production (Fig. 
13D). We can therefore conclude from the results presented above that IQGAP1 is 
required for the increased RAC1-GTP levels, the high inflammatory signaling 
cascade, and the arthritis of in Pggt1bΔ/Δ macrophages. 
TIAM1 contributes to increased RAC1-GTP loading and cytokine production 
of GGTase-I-deficient macrophages 
Because IQGAP1 does not have GEF or GAP activity, we next assessed whether 
another RAC1-specific GEF is involved. We found that non-prenylated RAC1 
binds more strongly with T-cell Lymphoma and metastasis 1 (TIAM1), a known 
guanine exchange factor (GEF) which converts RAC1 to its GTP-bound form (Fig. 
14A). Furthermore, we investigated the functional importance of this increased 
interaction. Knockdown of TIAM1 expression with small-interfering RNAs 
(siRNAs) reduced RAC1-GTP levels (Fig. 14B) and also reduced IL-1β cytokine 
production in GGTase-I knockout macrophages (Fig. 14C). We also demonstrate 
that TIAM1 binds to IQGAP1 and that this interaction was increased in Pggt1bΔ/Δ 
macrophages (Fig. 14D). 
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Fig. 14. TIAM1 associated strongly with np-RAC1 and IQGAP1 in GGTase-I knockout 
macrophages and then contributed to RAC1-GTP loading and cytokine production (A) 
Immunoprecipitation analysis showing RAC1 interaction with TIAM1 in Pggt1bΔ/+ and Pggt1bΔ/Δ 
macrophage lysates. (B) Immunoblots showing the levels of RAC1-GTP from Pggt1bΔ//+ and 
Pggt1bΔ/Δ and TIAM1 knockdown Pggt1bΔ/Δ macrophage lysates. Actin was used as loading control, 
and np-RAC1 was used as a marker to indicate the absence of GGTase-I in macrophages. (C) IL-1β 
cytokine levels, after 8 hours of stimulation with LPS, from supernatants of Pggt1bΔ/+, Pggt1bΔ/Δ 
and Tiam1 knockdown Pggt1bΔ/Δ bone marrow-derived macrophages. (D) Immunoprecipitation 
analysis showing TIAM1 interaction with IQGAP1 in Pggt1bΔ/+ and Pggt1bΔ/Δ macrophage lysates.  
* P < 0.05, ** P < 0.01, *** P < 0.001. 
Conclusion 
Hyperactive RAC1 mediated both pro-inflammatory signaling in vitro and 
inflammation and arthritis in mice lacking Pggt1b in macrophages in vivo. Non-
prenylated RAC1 became GTP-bound through an increased interaction with 
IQGAP1 and TIAM1. The results suggest that IQGAP1 and RAC1 could drive 
inflammatory processes in conditions where prenylation is inhibited and raise the 
possibility that inflammatory disorders, such as MKD, that exhibit high levels of 
activated RAC1, could be treated with IQGAP1 or RAC1 inhibitors. 
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Statistics 
Values are represented to mean and SEM. Significance difference between the 
groups are analyzed by student t-test or one-way ANOVA with Tukey´s post hoc 
test. Significance difference less than 0.05 are considered as significant. * P < 0.05, 
** P < 0.01, *** P < 0.001. 
 
 41 
 
7 DISCUSSION 
In paper I, we showed the underlying molecular mechanisms involved in the control 
and regulation of excessive innate immune responses in GGTase-I-deficient 
macrophages. In paper II, we showed the importance of RAC1 in inflammatory 
phenotypes in mice lacking GGTase-I in macrophages and also investigated 
potential mechanisms on how non-prenylated RHO proteins become GTP-bound. 
These studies increase our understanding of the biochemical and medical 
importance of GGTase-I-mediated prenylation. Our data suggested that one role of 
prenylation in macrophages is to restrain innate immune reactions by limiting 
RAC1 effector interactions.  
The role of GGTase-I in macrophages for innate immunity 
Macrophages are considered as crucial mediators to trigger innate immune 
responses (186). In the first part of my PhD, I evaluated the importance of 
macrophage-specific GGTase-I in innate immune responses. The PI(3)K-Akt-
Gsk3β and mTOR signaling pathways are important contributors for TLR-induced 
immune responses via productions of inflammatory mediators, and they emerged 
as crucial regulators in sensing of immune cells (241-243). However, the underlying 
molecular mechanisms behind inflammatory signaling of PI3K-AKT-GSK3β and 
mTOR kinase cascades are not clearly understood.  Previous studies identified B-
cell adaptor protein for PI3K (BCAP) required for activation of PI3K signaling 
triggered by Myd88-dependent TLRs (TLR4, TLR7 and TLR9) (244, 245). It is 
unclear whether TLR3 follows similar mechanisms to activate PI3K signaling. 
TLR3 directly recruits PI3K to its cytoplasmic tails via specific phosphorylation of 
tyrosine residues present in cytoplasmic domain of TLR3 (246). We found that 
there is an altered balance between the production of inflammatory cytokines (IL-
1β, IL-6 and TNFα) and anti-inflammatory cytokines (IL-10 and IFN-β) in response 
to TLR ligands (LPS and Poly:IC) in GGTase-I knockout macrophages. We further 
noticed impaired signaling of PI3K-AKT-GSK3β, mTOR kinase cascades in 
response to TLR ligands in GGTase-I knockout macrophages. These results are 
consistent with previous published data, in which PI3K is essential for production 
of IFN-β  via reduced activation of GSK3β (247-249). These results suggested that 
GGTase-I is required for PI3K signaling and for the maintenance of the balance 
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between inflammatory and anti-inflammatory cytokine production via Myd88- 
dependent and -independent signaling. 
Previous studies have shown that RAS, an oncogene, can directly interact with RBD 
(Ras-binding domain) of PI3K and this interaction is essential for normal and 
malignant cell growth (250, 251). In addition to that, a few studies reported that 
RAS and PI3K interaction is responsible for both physiological and pathological 
consequences of PI3Ks (251). However, it is unclear yet, how this interaction 
contributes to TLR induced innate immune responses. Three decades ago, the 
finding that farnesylation of RAS is required for RAS oncogenic transformation 
caught much attention in scientific world and led to the development of FTIs as 
discussed earlier. By contrast, clinical trials with FTIs showed no promise against 
treating cancers and it mainly due to change in prenylation status of KRAS when 
cells lack FTase I. (59, 252, 253). In this study, we found that reduced RAS 
activation of PI3K could explain the reduced AKT activation and increased 
inflammasome activation in GGTase-I-deficient macrophages. And one potential 
explanation for that could be that a specific pool of geranylgeranylated KRAS 
normally stimulates PI3K-AKT signaling in macrophages and that this pool in 
inactivated in GGTase-I-deficient macrophages. Previously, our lab showed that 
knockout FTase-I in myeloid cells had no effect on KRAS functional activity (29), 
and more importantly lack of FTase-I had no aberrant effect on immune cell 
function (48). Our lab showed myeloid cell-specific knockout of both FTase-I and 
GGTase-I in mice had inflammatory phenotype similar to GGTase-I knockout in 
macrophages (48). Together with the above results and our data indicated that 
GGTase-I controls the interaction between KRAS and p110δ and this interaction 
responsible for controlling signaling cascades responsible for inflammation.  
Previous research has shown that defects in LPS induced internalization and 
subcellular trafficking of TLR4 in dendritic cells lacking p110δ (244).  We found that 
no such defects in GGTase-I deficient macrophages even though PI3K-AKT 
signaling was impaired in GGTase-I-deficient macrophages and this mainly due to 
difference in cell types that we examined. Moreover, p110δ-knockout macrophages 
produced high amounts of inflammatory cytokines and lower amounts of IFN-β, 
suggesting that those macrophages phenocopy GGTase-I knockout macrophages. 
We noticed similar results of increased inflammatory cytokine productions in 
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statin-treated macrophages suggested that the role of unprenylated proteins in 
increased inflammatory cytokine productions.   
We noticed that increased basal activity of IBα in GGTase-I-deficient 
macrophages indicating increased NFB activity via increased activity of RELA. 
Furthermore, increased GSK3β activity in GGTase-I-deficient macrophages 
supports activation of NFB via reduced activation of AKT signaling. The PI3K-
AKT-GSK3β and mTOR signaling pathways are pivotal for normal cellular 
functions that includes proliferation, survival and metabolism. Aberrant signaling 
of PI3K are noticed in several human diseases, and our data shed at least some light 
on the importance of the mevalonate pathway in these signaling pathways. 
The main criticism of this paper is that we provide no conclusive evidence that 
KRAS is geranylgeranylated under normal circumstances. Moreover, there is no 
solid evidence in the literature of KRAS geranylgeranylation, other than in FTI-
treated cells. And although absence of evidence is not evidence of absence; clearly, 
more studies are required to understand the role of p110δ, KRAS, and AKT-
signaling for the inflammatory phenotypes of GGTase-I-deficient macrophages.  
RAC1 contributes to erosive arthritis in GGTase-I knockout mice 
During the second part of my PhD, we set out to identify the cellular mechanisms 
behind erosive arthritis in mice lacking GGTase-I in macrophages. Our data 
revealed new insights of physiological and biochemical consequences of blocking 
GGTase-I in immune cells. GGTase-I prenylates several dozen CAAX proteins 
(perhaps more than 60) and our data revealed that only one of them, RAC1, is 
responsible for the main phenotypes. Even though arthritis was significantly 
reduced in RAC1 knockout mice (to a level that was actually statistically 
indistinguishable from wild-type controls), it was not eliminated completely, 
indicating that other RAC isoforms, such as RAC2, might be involved in the 
residual inflammation. 
Prenylation is believed to be important for RHO family protein function such as 
membrane trafficking, activation of RHO proteins, and their interactions with 
effectors (1). Many studies supported the argument that prenylation is required for 
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RHO family function. Contrary to that, our study identified several important things 
on how unprenylated proteins behave in cells that goes against previous arguments.   
First, in our earlier studies non-prenylated RAC1 was hyperactive, and its 
membrane targeting was functional in GGTase-I knockout macrophages (and we 
proved with metabolic labeling that RAC1 was not prenylated) (48). In support of 
that, we found in the current study that RAC1 is hyperactive and targeted to 
membranes in HEK cells harbouring nonprenylated RAC1 mutations in the 
presence of normal GGTase-I activity. The only main deviation in cellular 
localization is that we consistently find RAC1 in the nucleus of normal 
macrophages, but in multiple studies, we see that endogenous nonprenylated RAC1 
is excluded from the nucleus. This finding goes against a wide-spread belief that 
non-prenylated RAC1 accumulates in the nucleus, a result that comes from 
expressing GFP-tagged exogenous forms of the protein (254).  
Second, consistent with previous results, we showed that non-prenylated RAC1 
accumulate in its active GTP-bound form in GGTase-I knockout macrophages; and 
in the present study, we add that total levels of RAC1 are consistently reduced – 
which leads to a marked increase in RAC1 specific activity. The reduction of total 
RAC1 is likely due to increased ubiquitin-mediated degradation of RAC1-GTP in 
GGTase-I knockout macrophages, an effect that was controlled by IQGAP1.   
Third, our studies showed that increased levels of GTP-bound and total 
nonprenylated RHOA and CDC42, even though these proteins did not appear to 
contribute to the inflammatory phenotype in GGTase-I knockout mice. These 
results suggested that blocking geranylgeranylation differentially regulates 
degradation of RHO proteins; the precise mechanisms underlying stabilization of 
total levels of RHOA and CDC42 needs to be investigated further, but again we 
found clear evidence that it is regulated by IQGAP1. It is possible that IQGAP1 can 
target some GTP-bound RHO proteins to degradation and protect others.  
Fourth, our studies showed that blocking prenylation leads to sustained activation 
of RAC1. Activation of RAC1 triggered production of inflammatory cytokines 
activated pyrin and caspase-1-dependent inflammasome signaling (Figure 14).  
These increased inflammasome signaling clearly underlies the increased production 
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of mature IL1β. Altogether, our data suggest that blocking RAC1 
geranylgeranylation leads to inflammatory phenotypes in GGTase-I knockout mice.  
Previous studies reported a reduced association between nonprenylated RAC1 and 
RHOGDI1 (48). Another earlier study showed that RAC1-GTP levels are increased 
in cells where RHOGDI1 expression was suppressed by siRNAs (255). This raises 
the possibility that RAC1 in GGTase-I-deficient cells interacts less with RHOGDI1 
and that this explains the increased GTP-loading. We tested this possibility in great 
detail in three different macrophage cell lines by both siRNAs and CRISPR/CAS9-
mediated knockout of RHOGDI1. We found that knockdown of RHOGDI1 
increased RAC1-GTP in one of the three cell lines and that this led to increased 
production of IL-6 and TNFα in response to LPS, but IL1 was not produced. Thus, 
we concluded that RHOGDI1 is likely not involved in the main phenotypes of 
GGTase-I deficiency. Instead, the phenotypes are explained by an increased 
association between RAC1, IQGAP1, and TIAM1.  
Previous studies reported that IQGAP1 preferentially binds and stabilize to RAC1 
in its GTP form (147) (256). We found that IQGAP1 binds stronger to non-
prenylated RAC1 and that TIAM1 is the main GEF involved. We also found that 
IQGAP1 is essential for development of inflammatory phenotypes in macrophage-
specific GGTase-I knockout mice. Indeed, knockout of IQGAP1 reduced 
inflammatory phenotypes; reduced levels of GTP-bound RHO proteins; and 
normalized total levels of RHO proteins in GGTase-I knockout macrophages. 
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Fig. 15. The mevalonate pathway controls the innate immune response through 
geranylgeranylation of RAC. Geranylgeranyl pyrophosphate is an important intermediate 
produced by the mevalonate pathway. GGTase-I uses GGPP for prenylation of RHO family proteins. 
GGTase-I limits RAC1signaling (RAC1-p38-Nf-KB) to control cytokine production and Mefv 
inflammasome formation. 
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Nonprenylated RAC1 had a high affinity for IQGAP1, and this interaction was 
essential for in vitro and in vivo phenotypes. This raises the interesting possibility 
that targeting IQGAP1 might be an effective strategy to treat auto-inflammatory 
disorders like HIDS and MKD in which there is evidence of reduced prenylation. 
Earlier research suggests RAC1 inhibitors might be useful in the treatment of MKD 
patients but knockout of RAC1 is lethal, and it causes several cellular phenotypes 
in mice. Thus, we propose that IQGAP1 might be worthwhile testing. IQGAP1 is 
not essential for mouse development and in our studies, we find that cytokine 
production by IQGAP1-deficient macrophages was normal (Figure S5). 
Statin treatment of macrophages consistently produced similar phenotypes as 
GGTase-I deficiency in our experiments. Some of those statin effects have been 
observed in earlier studies, but no clear mechanism has been established (218, 257). 
Here we clearly link statin effects to IQGAP1 because statin effects were blunted 
or abolished in Iqgap1-deficient cells. Most studies conclude that statins have anti-
inflammatory rather than pro-inflammatory effects. We discuss this issue in the 
Paper II and propose that statins anti-inflammatory effects might be caused by 
blocking prenylation in lymphocytes rather than macrophages. Moreover, we 
propose that side-effects of statin therapy might be caused by reduced prenylation 
and hyperactivation of RHO family proteins. Side effects are observed in more than 
10% of people treated with statins (i.e., many hundred thousand patients) and range 
from muscle pain (myositis, common) to rhabdomyolysis (rare) and death.  
The main criticism of this study is that we didn’t reveal whether RAC1 becomes 
GTP-bound before or after binding to IQGAP1. On one hand, RAC1 could be GTP-
loaded by TIAM1 immediately after synthesis and then become bound to IQGAP1. 
On the other hand, RAC1 could first be recruited to IQGAP1, encounter TIAM1 
and then become GTP-bound. Our results do not clearly distinguish between those 
possibilities. It would also be interesting to create a RAC1 mutant that is incapable 
of binding IQGAP1 (or vice versa) and determines if this would still lead to 
increased RAC1-GTP loading and pro-inflammatory signaling. It would be 
informative to analyze mice expressing constitutively active RAC1 in macrophages 
(or ubiquitously) and determine if increased RAC1-GTP levels are sufficient to 
produce arthritis or if RAC1 also has to be unprenylated.  
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8 FUTURE DIRECTIONS 
Previously, we reported that mice lacking Pggt1b in macrophages develop erosive 
arthritis; and now we have shown that knockout of one copy of Rac1 significantly 
reduces disease symptoms in joints of Pggt1bΔ/Δ mice.  
One of the most prominent hallmarks of Pggt1b-deficient macrophages is the 
accumulation of non-prenylated proteins such as RAC1, RHOA and CDC42 in the 
active GTP-bound form; and the associated TLR-agonist-induced production of 
pro-inflammatory cytokines. To further determine if RAC1 alone mediates 
inflammation, we need to eliminate the possibility that any one of the other 50-100 
GGTase-I substrates (that also accumulates in the non-prenylated form in the cells) 
are not involved. To accomplish this, we will engineer an endogenous CAAX-
mutant form of Rac1 and express it ubiquitously in mice or only in macrophages or 
lymphocytes. For this, we will use CRISPR/CAS9 or conventional gene-targeting 
in ES cells to create a mutation in the Rac1 gene that will lead to the production of 
RAC1C190S and RAC1C190Δ which will not be prenylated. If such “Rac1-SLLL” 
mice develop arthritis, we would have proven this point. If they don’t, we need to 
understand why. 
We also need to address an important unanswered question relating to Paper I: how 
could the absence of GGTase-I reduce the interaction between KRAS and p110δ 
given that neither of these two proteins should be affected by the absence of 
GGTase-I? Although KRAS can be geranylgeranylated by GGTase-I, it is a better 
substrate for FTase. One theory, proposed from Paper I, is that there is a pool of 
KRAS that is normally exclusively prenylated by GGTase-I and that this pool 
becomes non-prenylated in the GGTase-I-deficient macrophages—and that non-
prenylated KRAS interacts poorly with p110δ. Another theory would be that 
hyperactive RAC1 influences the KRAS-p110δ interaction in the absence of 
GGTase-I. In the future, we plan to address these issues in a definitive fashion and 
further increase our understanding of the role of CAAX protein prenylation in 
mammalian cells. 
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